{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:22Z","timestamp":1790744482148,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Oxaliplatin-induced hypersensitivity reactions (HSRs) can interrupt clinically indicated treatment for gastrointestinal malignancies. We evaluated the early implementation of a multidisciplinary oxaliplatin desensitization pathway at Vinmec Times City International Hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective case series of patients who underwent oxaliplatin desensitization between 2022 and 2025 following an index HSR. Clinical characteristics, skin testing results, desensitization procedures, breakthrough reactions (BTRs), and subsequent oxaliplatin treatment completion were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten patients underwent desensitization after index HSRs occurring at a median of six oxaliplatin cycles (range, 2\u201311); six index reactions were Brown grade 2. Skin prick testing was negative in all patients, whereas intradermal testing was positive in six, negative in three, and equivocal in one. Three patients initially underwent a three-bag desensitization procedure and seven a four-bag procedure. Eight BTRs occurred in six patients, none requiring epinephrine. Seven patients completed all additional oxaliplatin cycles planned by their oncology team, receiving a median of four additional cycles. Three patients discontinued oxaliplatin after BTRs: two because of recurrent reactions despite procedure modification and one because the patient declined further treatment after a single BTR in the metastatic setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Multidisciplinary oxaliplatin desensitization enabled most patients in this early case series to continue and complete planned oxaliplatin treatment, although BTRs were common. Given the small, retrospective cohort, these findings are descriptive and require further study to establish comparative safety or efficacy, superiority of a specific desensitization procedure, or predictors of treatment completion.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1876656","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:47:51Z","timestamp":1790743671000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Oxaliplatin desensitization for gastrointestinal cancer patients with hypersensitivity reactions: real-world experience from Vietnam"],"prefix":"10.3389","volume":"16","author":[{"given":"Le Trang","family":"Nguyen","sequence":"first","affiliation":[{"name":"Pharmacy Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]},{"name":"College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Thang","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]},{"name":"College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong Thach","family":"Nong","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Thanh Dat","family":"Doan","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Tuan","family":"La","sequence":"additional","affiliation":[{"name":"Hanoi University of Pharmacy","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi Mai","family":"Vu","sequence":"additional","affiliation":[{"name":"College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Allergy and Immunology Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Thien","family":"Le","sequence":"additional","affiliation":[{"name":"Vinmec-VinUni Institute of Immunology, College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Center for Innovations in Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Vinmec Healthcare System","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh Dung","family":"Quach","sequence":"additional","affiliation":[{"name":"College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Oncology Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quynh Lan","family":"Phan","sequence":"additional","affiliation":[{"name":"College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Vinmec Healthcare System","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Dinh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]},{"name":"Vinmec-VinUni Institute of Immunology, College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngoc May","family":"Le","sequence":"additional","affiliation":[{"name":"College of Health Sciences, VinUniversity","place":["Hanoi, Vietnam"]},{"name":"Oncology Department, Vinmec Times City International Hospital","place":["Hanoi, Vietnam"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"B1","unstructured":"Oxaliplatin injection, solution, concentrate: prescribing information\n          \n          \n          Dailymed\n          \n          2021"},{"key":"B2","unstructured":"NCCN clinical practice guidelines in oncology: colon cancer. Version 2.2026\n          \n          \n          Plymouth Meeting (PA)\n          National Comprehensive Cancer Network\n          \n          2026"},{"key":"B3","unstructured":"NCCN clinical practice guidelines in oncology: gastric cancer. Version 3.2026\n          \n          \n          Plymouth Meeting (PA)\n          National Comprehensive Cancer Network\n          \n          2026"},{"key":"B4","unstructured":"NCCN clinical practice guidelines in oncology: rectal cancer. Version 2.2026\n          \n          \n          Plymouth Meeting (PA)\n          National Comprehensive Cancer Network\n          \n          2026"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1624322","article-title":"Independent risk and protective factors for oxaliplatin-induced hypersensitivity reactions: a retrospective study","volume":"16","author":"Xue","year":"2025","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/all.15940","article-title":"Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization","volume":"79","author":"Jimenez-Rodriguez","year":"2024","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/all.16296","article-title":"Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes","volume":"80","author":"Bogas","year":"2025","journal-title":"Allergy"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/all.16607","article-title":"Basophil activation test: bridging allergy and oncology for diagnostic, therapeutic and prognostic applications in AllergoOncology: an EAACI position paper","volume":"80","author":"Pascal","year":"2025","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.12.917","article-title":"Skin test protocol for the prevention of hypersensitivity reactions to oxaliplatin","volume":"34","author":"Pagani","year":"2014","journal-title":"Anticancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1159\/000107467","article-title":"Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin","volume":"145","author":"Pagani","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.04.029","article-title":"Clinical features and severity grading of anaphylaxis","volume":"114","author":"Brown","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.021","article-title":"Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients","volume":"41","author":"Maindrault-Goebel","year":"2005","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity reactions related to oxaliplatin","volume":"89","author":"Brandi","year":"2003","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.07.031","article-title":"A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents","volume":"7","author":"Madrigal-Burgaleta","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.11.006","article-title":"Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy","volume":"5","author":"Giavina-Bianchi","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0425","article-title":"Does rapid drug desensitization to chemotherapy affect survival outcomes","volume":"30","author":"Berges-Gimeno","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.jaip.2015.12.019","article-title":"Safety, costs, and efficacy of rapid drug desensitizations to chemotherapy and monoclonal antibodies","volume":"4","author":"Sloane","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.anai.2020.04.017","article-title":"Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: outcomes and risk factors","volume":"125","author":"Caiado","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2026.1751512","article-title":"Comparison of rapid and same-day desensitization protocols in hypersensitivity reactions to platinum and taxanes: a retrospective cohort study","volume":"7","author":"Torres G\u00f3rriz","year":"2026","journal-title":"Front Allergy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/all.16353","article-title":"Medical algorithm: diagnosis and treatment of drug hypersensitivity reactions to biologicals, 2024 update","volume":"80","author":"Yang","year":"2025","journal-title":"Allergy"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0911","article-title":"Adjuvant use of omalizumab in desensitization to chemotherapeutics: beyond IgE-mediated reactions","volume":"33","author":"Prieto-Garc\u00eda","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.15586\/aei.v53i4.1349","article-title":"Rapid drug desensitization with chemotherapy: when should omalizumab be considered","volume":"53","author":"Bulut","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2025.10.001","article-title":"Influence of Lynch syndrome on the incidence of side effects to antineoplastic treatment of patients with colorectal cancer","author":"Alencar","year":"2025","journal-title":"Cancer Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2025.03.002","article-title":"HSP110 T17 marker matches the pentaplex panel and outperforms CAT-25 for detecting microsatellite instability in sporadic colorectal cancer","author":"Rajoua","year":"2025","journal-title":"Cancer Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.cancergen.2025.10.003","article-title":"The prevalence of TP53, APC, and PIK3CA gene mutations in colorectal cancer patients: a systematic review and meta-analysis","author":"Gheibi","year":"2025","journal-title":"Cancer Genet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:47:59Z","timestamp":1790743679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1876656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1876656"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1876656","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"1876656"}}